Orion Nutraceuticals (ORI) AI Stock Analysis

• Market Cap: C$797.31K
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.00
• Revenue Growth: N/A
• EPS Growth: -314.29%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 29,307,964
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: -13.54
• Price to Book (P/B): -10.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -123.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 21 Underperform
• Price Target: ―

Orion Nutraceuticals exhibits significant financial instability, with no revenue and consistent losses. The technical analysis indicates a lack of momentum, while the negative P/E ratio and absence of dividends highlight valuation challenges. The lack of earnings call and corporate events data further limits insights into potential positive catalysts.

Orion Nutraceuticals Business Overview & Revenue Model

Company Description

Orion Nutraceuticals (ORI) is a company operating in the health and wellness sector, specializing in the development and distribution of high-quality nutraceutical products. These products are designed to support overall health and wellness by leveraging natural and scientifically-backed ingredients. ORI focuses on creating supplements, functional foods, and herbal products that cater to a wide range of health needs, including general wellness, immune support, and targeted health solutions.

How the Company Makes Money

Orion Nutraceuticals generates revenue primarily through the sale of its nutraceutical products. The company's revenue model is based on direct sales to consumers through its online platform, as well as distribution partnerships with health stores and pharmacies. Key revenue streams include retail sales, subscription services for regular delivery of products, and wholesale agreements with healthcare providers. The company's earnings are bolstered by strategic partnerships with research institutions for product development and marketing collaborations with wellness influencers to expand its customer base.

Orion Nutraceuticals Financial Statement Overview

Summary

Orion Nutraceuticals is facing significant financial challenges, with no revenue generation and consistent losses impacting all aspects of its financial health. The balance sheet reflects high leverage and negative equity, while cash flow statements show persistent cash deficits, underscoring the need for strategic restructuring or new revenue streams to avoid further deterioration.

Income Statement

The company has consistently reported zero revenue across all periods, indicating no sales activity. Negative EBIT and EBITDA margins highlight significant operational inefficiencies. The net profit margin is also deeply negative, reflecting ongoing losses.

Balance Sheet

The balance sheet reveals negative stockholders' equity, implying financial instability and potential solvency issues. The company has a high debt-to-equity ratio, further increasing financial risk. The equity ratio is negative, emphasizing a precarious financial position.

Cash Flow

Operating and free cash flows are consistently negative, indicating insufficient cash from operations to cover expenses. The operating cash flow to net income ratio is negative, aligning with poor income performance. Financing activities occasionally provide cash inflow, but not enough to stabilize cash flow concerns.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-61.82K	-280.00K	2.06M	-883.00K	-386.00K
Net Income	-61.82K	-280.00K	-4.96M	-1.23M	-229.00K
Balance Sheet
Total Assets	193.46K	3.99K	9.43K	2.43M	584.97K
Cash, Cash Equivalents and Short-Term Investments	193.46K	3.99K	9.43K	280.19K	501.29K
Total Debt	82.24K	90.33K	44.00K	44.00K	44.00K
Total Liabilities	1.17M	918.97K	645.60K	449.28K	849.85K
Stockholders Equity	-975.87K	-914.05K	-635.25K	1.98M	-263.96K
Cash Flow
Free Cash Flow	-56.94K	-51.77K	-82.92K	-935.04K	-47.98K
Operating Cash Flow	-56.94K	-51.77K	-82.92K	-935.04K	-47.98K
Investing Cash Flow	254.50K	0.00	-187.83K	-2.40M	0.00
Financing Cash Flow	-8.10K	46.33K	0.00	3.11M	544.00K

Orion Nutraceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACB	57 Neutral	$370.10M	112.86	3.05%	―	26.98%	―
Sector *	52 Neutral	$7.58B	0.48	-62.71%	2.36%	15.33%	0.41%
WEED	45 Neutral	$315.66M	―	-122.10%	―	-18.39%	35.21%
ORI	21 Underperform	C$797.31K	―	6.34%	―	―	-314.29%